High-risk mantle cell lymphoma encompasses a subset of patients whose tumour biology demands a differentiated first-line strategy. Risk stratification based on molecular and morphological features is central to selecting the appropriate regimen.

Clinical Scenario

Patients with high-risk MCL are typically characterised by a high-risk MIPI score, high Ki67, blastoid or pleomorphic morphology, and/or a TP53 mutation or p53 overexpression. This combination of features defines a population for whom standard approaches may be insufficient and tailored first-line treatment selection is essential.

Treatment Approach — Partial Overview

In this setting, treatment selection is driven by p53 status and patient fitness, with approaches involving BTK inhibitor-based combinations for eligible patients — the complete regimen options, sequencing, maintenance strategy, and decision points by TP53/p53 status are detailed in the full protocol.

References

DOI: 10.1002/hem3.70233

Patients with high‑risk MCL are typically characterized by either a high‑risk MIPI score, high Ki67, blastoid or pleomorphic morphology, and/or a TP53 mutation or p53 overexpression.
Fit patients ≤ 70 years with p53 overexpression may be considered for R‑CHOP‑Ibrutinib/R‑DHAP/Ox induction +/−ASCT, followed by 2 years of ibrutinib and 3 years of rituximab maintenance [II, C].
Consider first‑line anti‑CD20, BTK inhibitor, and BCL2 inhibitor combinations for patients with TP53 mutations if available [III, B].
The combination of zanubrutinib, obinutuzumab, and venetoclax (BoVEN) demonstrated a complete response rate of 88% and a 2‑year progression‑free survival of 72%.

View source ↗

Treatment of Mantle Cell Lymphoma with High-Risk MIPI Score, High Ki67, Blastoid or Pleomorphic Morphology, or TP53 Mutation / p53 Overexpression

References